2026 ANSWERS GUARANTEED PASS
⫸ What is an AE? Answer: Adverse event (AE)
1. Any untoward medical occurrence in a patient or clinical investigation
subject administered a pharmaceutical product and which does not
necessarily have a causal relationship with this treatment. An adverse
event (AE) can therefore be any unfavourable and unintended sign
(including an abnormal laboratory finding), symptom, or disease
temporally associated with the use of a medicinal (investigational)
product, whether or not related to the medicinal (investigational)
product.
⫸ What is an SAE? Answer: Serious adverse event (SAE)
1. Results in death
2. Is life-threatening
3. Requires inpatient hospitalization or prolongation of existing
hospitalization
4. Results in persistent or significant disability/incapacity
5. Is a congenital anomaly/birth defect
⫸ What is an UADR? Answer: Unexpected adverse drug reaction
(UADR)
, 1. An adverse reaction, the nature or severity of which is not consistent
with the applicable product information (e.g., IB for an unapproved IP or
package insert/summary of product characteristics for an approved
product)
⫸ Who constitutes a vulnerable subject? Answer: Individuals whose
willingness to volunteer in a clinical trial may be unduly influenced by
the expectation of benefits associated with participation, or of a
retaliatory response from senior members of a hierarchy in case of
refusal to participate.
Examples are members of a group with a hierarchical structure, such as
medical, pharmacy, dental, and nursing students, subordinate hospital
and laboratory personnel, employees of the pharmaceutical industry,
members of the armed forces, and persons kept in detention.
Other vulnerable subjects include patients with incurable diseases,
persons in nursing homes, unemployed or impoverished persons,
patients in emergency situations, ethnic minority groups, homeless
persons, nomads, refugees, minors, and those incapable of giving
consent.
⫸ GCP: Clinical trials should be conducted in accordance with the
ethical principles that have their origin in the ___________ __
________, and that are consistent with GCP and the applicable
regulatory requirement(s). Answer: Declaration of Helsinki